Fennec Pharmaceuticals Inc. FENC
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +74.68%
- 1 year
- +64.43%
5D +2.85 (+27.19%)
- Market cap
- 474.85M
- Revenue (ttm)
- 49.35M
- Profit margin
- -2.30%
- EPS (ttm)
- 0.03
- Shares out
- 27.43M
- P/E ratio
- 448.33
- Forward P/E
- 16.78
- YTD return
- +74.68%
- 1-year return
- +64.43%
- Volume
- 460.51K
- Avg volume
- 214.60K
- Open
- 13.40
- Previous close
- 13.33
- Day's range
- 13.20 – 13.84
- 52-week range
- 5.65 – 13.85
- Beta
- 0.27
- Analysts
- Strong Buy
- Price target
- 13.60 (+1.1%)
Key statistics
- 50-day average
- 5.08
- 200-day average
- 6.71
- Enterprise value
- 156.10M
- Price / sales
- 3.45
- Revenue growth
- 7.00%
- Free cash flow
- -3.40M
- Total cash
- 40.32M
- Total debt
- 32.10M
- Short % of float
- 11.18%
Fundamental scorecard
12 of 25 checks passed on FENC’s reported financials
12of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.13 | -0.21 | -0.08 | -61.54% |
| Aug 13, 2024 | Jun 1, 2024 | 0.06 | -0.20 | -0.26 | -433.33% |
| May 14, 2024 | Mar 1, 2024 | 0.49 | 0.41 | -0.08 | -16.33% |
| Mar 21, 2024 | Dec 1, 2023 | 0.02 | -0.10 | -0.12 | -600.00% |
| Nov 6, 2023 | Sep 1, 2023 | -0.11 | -0.07 | +0.04 | +36.36% |
| Aug 3, 2023 | Jun 1, 2023 | -0.18 | -0.21 | -0.03 | -16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fennecpharma.com
News
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $17
Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable
H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19
What Makes Adherex Technologies (FENC) a New Strong Buy Stock
How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%
Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
Adherex Technologies Q3 Earnings Call Highlights
Fennec Pharmaceuticals Q3 2026 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates
Your note
Sign in to keep a note on FENC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDRADE ROBERT C | Chief Financial Officer | Stock Award(Grant) | Dec 1, 2024 | 128,423 |
| HAIGH ADRIAN J | Chief Operating Officer | Conversion of Exercise of derivative security | Apr 21, 2024 | 0 |
| ISLAM KHALID | Director | Conversion of Exercise of derivative security | Nov 15, 2023 | 213,825 |
| RALLIS CHRISTOPHER ANIGERON | Director | Conversion of Exercise of derivative security | Dec 1, 2024 | 52,214 |
| RAYKOV ROSTISLAV CHRISTOV | Director | Sale | Dec 4, 2024 | 66,432 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Southpoint Capital Advisors Lp | 14.84% | 4,077,214 | 25.32M | Sep 29, 2024 |
| Sonic Gp LLC | 8.76% | 2,407,357 | 14.95M | Sep 29, 2024 |
| Solas Capital Management, LLC | 7.00% | 1,923,536 | 11.95M | Sep 29, 2024 |
| DG Capital Management, LLC | 5.54% | 1,522,204 | 9.45M | Sep 29, 2024 |
| Blackrock Inc. | 4.48% | 1,229,477 | 7.64M | Sep 29, 2024 |
| Vanguard Group Inc | 3.81% | 1,047,891 | 6.51M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.19% | 876,208 | 5.44M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.04% | 559,371 | 3.47M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 241,018 | 1.50M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.60% | 165,510 | 1.03M | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.34% | 94,580 | 587.34K | Aug 30, 2024 |
| Schwab Capital Trust-Small Cap Index Fund | 0.20% | 55,452 | 344.36K | Jul 30, 2024 |
